Introduction Capmatinib, a highly selective MET inhibitor, in a patient with advanced non-small-cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation (1). It underscores the importance of molecular profiling in guiding targeted therapy and demonstrates capmatinib's rapid and durable efficacy, consistent with findings from the GEOMETRY
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2601 Reached1 Comments4 Likes
Total Hip Arthroplasty in a Patient with Congenital Insensitivity to Pain
358 Reached4 Comments5 Likes
Chronic Cough in Adolescent
282 Reached1 Comments6 Likes